Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...

Teriflunomide treatment incurred an unadjusted risk reduction of 63% and an adjusted risk reduction of 72% in inhibiting a first clinical demyelinating event in patients with multiple sclerosis (MS).

Late-onset multiple sclerosis (MS) has poorer prognostic features but often lacks the inflammatory demyelination that is a target for treatment in younger patients. Investigators analysed data from ...

EDINBURGH, Scotland--(BUSINESS WIRE)--Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological ...

"Our findings prompt the inevitable question of whether the current phenotype classification of relapse-onset MS into relapsing-remitting and secondary progressive MS is as useful as we thought, for ...

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...

While diagnostic criteria for typical multiple sclerosis (MS) perform well in people ages 18 to 50, differential diagnoses in ...